467 results about "Hypodermoclysis" patented technology

A hypodermic drug delivery apparatus (10) for delivering a pressurized medication fluid (23) comprising a reservoir (14) containing at least one deliverable fluid (23) and a rupturing member (25) the reservoir (14) having at least one portion of at least one wall (22) rupturable by the rupturing member (25).

A storage system for a needleless pen delivery device syringe and a hypodermic needle adapted for attachment to and use with the pen delivery device syringe. A tubular sleeve has a first hollow chamber for receiving therein the needleless pen delivery device syringe, and a hollow cap has a second hollow chamber for receiving therein the hypodermic needle. The cap is adapted to affix to the sleeve to form a continuous tubular housing, and the sleeve is adapted to receive the pen delivery device syringe only when the needle is not attached to the syringe. Alternative exemplary embodiments provide means for storing other related accessories or additional spare needles.

An apparatus for subcutaneous administration of an injectable product, including a housing, a container for the product to be injected, an injection needle and a needle protection sleeve surrounding the injection needle, wherein the apparatus also includes an indicator to tell a user when the needle protection sleeve has attained its maximum distal position.

An ice coating is placed on the hypodermic needle to cool the flesh during insertion. The ice coated front end is sharp, for penetration. The ice coating can be formed by cooling the needle and dipping it in water or molding ice onto the needle. A refrigeration chamber or cryogenic chamber can be used to cool the needle. The mold for forming an ice coating can be cooled by a cryogenic fluid or refrigerant being conducted into coils of the mold surrounding heat conducting mold walls that are used to form the ice coating on the needle. The water can be sterilized with disinfectant included.

Apparatus and method for catheterized delivery or infusion of medication and anaesthesia are disclosed. The perforating catheter is first used to perforate the periodontal ligament and/or the cortical plate of bone tissue, and is then left in place and used as a catheter for insertion of a hypodermic needle of smaller gauge to deliver medication or anaesthesia to a target area. The perforator is a bevelled needle for drilling into the ligament or bone tissue. For drilling, the device comprises an adaptor which transmits the rotational movement from a dental hand piece or the like to the bevelled needle. A cap is also included for protecting the bevelled needle during storage of the device. The adaptor may have a rod which extends axially into the bevelled needle when the device is assembled for drilling. The rod is used to prevent the debris resulting from drilling from blocking the passage in the bevelled needle. As well, the rod reinforces the needle and maintains the alignment between the perforator and the adaptor for improved drilling efficiency. An adapter is disclosed which couples with the catheter once in place easing access to supply medication to difficult to reach areas.

A needle assembly includes a sheath into which a hypodermic needle is withdrawn in a protected position. Installation of the needle assembly onto a Luer lock causes the needle to be thrust forward out of the sheath. A spring urges the needle to the withdrawn position. An elastomeric ball in the needle assembly provides sealing.

Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C_max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

A hypodermic injection system particularly for use in mass immunizations having a handpiece with a grasping mechanism for holding ampules filled with injectate, a plunger for driving into the ampule to discharge the injectate in an injection process, an injection spring mechanism for driving the plunger, a motor and/or manual mechanism for cocking the injection spring mechanism, and an ampule ejection mechanism for ejecting ampules after use under control of a release mechanism. Ampules can be loaded, used and ejected without contact by the user of the system or the patient being injected. Also disclosed are a filling station for filling ampules through their injection orifices, and an arming device for setting the injection spring. Ampules are disclosed having a piston which is drivable towards an orifice to discharge injectate through the orifice. Ampules are also disclosed having enlarged proximal portions for easy grasping by the grasping mechanism of the injector. Ampules are further disclosed with separators for mixing lyophilized medication and a diluent. Further disclosed are magazines for holding ampules for sequential use by the hypodermic injector. The disclosed system finds particular use as a mass immunization kit for making numerous injections in the field.

The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.

Vacuum break vial assembly and method for reducing the incidence of nosocomial infections, comprising a vial stopper having a 2-part withdrawn-fluid volume compensation assembly having a barbed vent element that secures an apertured needle sheath, a bladder-retainer tube and an expandable/unfoldable bladder. The vial has an aluminum cap holding a plastic flip-off top that removes a central portion of the cap to permit access by hypodermic needle through the stopper into the needle sheath. No pre-pressurization of the vial by ambient contaminated air via the hypodermic can occur. Rather, the needle is inserted in the vial through the stopper and the medicinal fluid withdrawn. Air is inlet into the separate bladder which expands to permit withdrawal of fluid into the hypodermic without vacuum lock. No air having pathogen vectors is introduced into the vial medicinal fluid as the bladder isolates volume-compensating air from the medicinal fluid. Plural embodiments are shown.

A non-volatile lubricious coating composition is provided for use with medical devices, such as hypodermic needles, catheters, and the like. The coating composition includes a first siloxane polymer having a very low viscosity less than about 50 centistokes, a second siloxane polymer having a high viscosity greater than about 1,000 centistokes, a reactive silicone polymer which is capable of crosslinking upon exposure to radiation, such as a UV curable silicone acrylate, and a photoinitiator to accelerate cross-linking of the reactive silicone polymer. The coating composition may further include an aminofunctional siloxane polymer to promote adhesion to metal surfaces when used with needles. The coating composition provides flowability without the need for any volatile organic solvent, and is capable of curing to provide adhesion and lubricity.

Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.

A needle point protective device for hypodermic and intravenous needles, catheter introducers, and similar devices protects users from injury and infection. The needle point protective device includes a needle point guard that is slidably mounted within the needle handle. In use, the needle point guard is integral with a cannula guide that is engaged with the needle cannula with enough force to cause the needle cannula to be subject to spring tension when the needle point is retracted proximal to the needle point guard, the needle point springs downward and behind the needle point guard. In one embodiment, the needle point guard is held in position manually as the needle is retracted. In another embodiment, the needle point guard is held in place automatically as the needle is retracted.

A fluid delivery and extraction device enables the remote transfer of fluid to or from biological tissue. The device comprises an elongated member, a syringe movable relative to the elongated member and a pair of hypodermic needles movable relative to the elongated member. The elongated member has a distal portion which is adapted to be inserted into a biological structure. A steer wire or guide wire can be used to navigate the distal portion within cavernous biological structures, particularly body lumens. The distal portion has at least one retractable hypodermic needle that is configured to pierce the interior surface of a tubular biological structure and transfer fluid to or from the walls of the tubular biological structure. A physician can use a handle or other control mechanism provided at a proximal portion of the device to remotely move the hypodermic needles. A plunger can be used to transfer fluid through the hypodermic needles to or from the syringe. In operation, the hypodermic needles are deployed simultaneously or individually from the distal portion of the device. As the hypodermic needles move, they pierce the interior surface of the tubular biological structure. The hypodermic needles can also be configured to pass beyond the exterior surface of the tubular biological structure. The plunger is then used to transfer fluid either from the syringe to the patient or from the patient to the syringe. The hypodermic needles are then moved back to their retracted positions within the distal portion, and the device is withdrawn from the patient's body.

Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patient's tissue glucose level, which in turn maintains the patient's blood glucose level within an optimum range. The formulation is often referred to as a “smart” formulation since it modifies its release rate of insulin according to the patient's needs at a particular time. In a preferred embodiment, the formulation is designed to release insulin into the systemic circulation over time with a basal release profile following injection in a patient. In another embodiment, the formulation is designed to release insulin into the systemic circulation over time with a non-basal release profile following injection in a patient, such as a regular human insulin release profile or a prandial release profile.

An apparatus for preventing blood exposure or contamination upon withdrawal of a hypodermic needle is provided. The apparatus may include a needle having a tip and a shield configured to at least partially entrap the needle tip upon withdrawal of the needle. The apparatus may further include a blood stabilizing material disposed such that upon withdrawal of the needle the blood stabilizing material is disposed in operative association with the needle tip such that blood carried by the needle is prevented from escaping the apparatus. In some exemplary implementations, the blood stabilizing material may be disposed on one or more surfaces of the shield. The shield of the hypodermic needle may include protective device and/or a housing for shielding the needle tip upon withdrawal. The housing may be adapted to at least partially cover the needle tip upon withdrawal of the needle. In some implementations, the housing may be adapted to allow the protective device to shield the needle before the needle is completely withdrawn.

Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention.